Cell lines established from the TH-MYCN transgenic murine model of neuroblastoma are a valuable preclinical, immunocompetent, syngeneic model of neuroblastoma, for which knowledge of their p53 pathway status is important. Trp53 status and functional response to Nutlin-3 and ionising radiation (IR) were determined in 6 adherent TH-MYCN transgenic cell lines using Sanger sequencing, immunoblotting and flow cytometry. Sensitivity to structurally diverse MDM2 inhibitors (Nutlin-3, MI-63, RG7388 and NDD0005) were determined using XTT proliferations assays. 2/6 cell lines were Trp53 homozygous mutant (NHO2A and 
Introduction
Neuroblastoma, an embryonal malignancy of the developing sympathetic nervous system, remains one of the most difficult paediatric cancers to cure with less than 50% of highrisk patients being long-term survivors despite intensive multi-modal therapy. MYCN amplification occurs in ~50% of high-risk cases, associating with rapid tumour progression and a poor prognosis (1) . The role of MYCN in neuroblastoma tumorigenesis was demonstrated by the generation of TH-MYCN transgenic mice in 1997 through transfer of a construct incorporating human MYCN cDNA under the control of the rat tyrosine hydroxylase promoter into the nucleus of fertilised murine oocytes and subsequent integration into genomic DNA (2, 3) . The tyrosine hydroxylase promoter leads to tissue-targeted overexpression of human MYCN to neural crest cells, and mice develop spontaneous highly penetrant abdominal and para-spinal thoracic tumours consistent with the sites of human neuroblastoma (2) . Tumour penetrance and growth have been shown to be related to MYCN gene dosage where homozygotes developed tumours with increased incidence and decreased latency (2, 4) . Analysis of the TH-MYCN tumours show that they recapitulate many histological features of human neuroblastoma with varying degrees of neuronal differentiation and expression of synaptophysin and neuronspecific enolase (2) . Moreover, tumours also exhibit chromosomal changes syntenic with those observed in human neuroblastoma tumours such as gain of chromosome 17 (2, 4) . The TH-MYCN transgenic mouse is now a well-established model of neuroblastoma, and a panel of homozygous and hemizygous TH-MYCN cell lines have been derived from tumour resections from these mice, similarly reflecting both the genetic and biological features of human neuroblastoma (5) . Although micrometastases can occur, one major limitation of the TH-MYCN transgenic model in preclinical drug development studies is the very low incidence of clinically relevant metastases to sites such as bone marrow, thus limiting its usefulness as a model for high-risk metastatic neuroblastoma (6) . To overcome this, TH-MYCN cell lines have been used to generate highly valuable orthotopic and pseudometastatic syngeneic models of neuroblastoma in an immunoproficient background (7, 8) . This is particularly important as immunotherapies such as anti-GD2 antibody are now standard of care for treatment of children with high-risk neuroblastoma.
The tumour suppressor gene TP53 is critical in maintaining genomic stability and is mutationally inactivated in >50% of all human malignancies (9) . Abnormalities in the p53 pathway can contribute to tumour resistance against ionising radiation (IR) and cytotoxic chemotherapies (10) (11) (12) (13) . In neuroblastoma tumours and cell lines established at diagnosis, TP53 mutations are rare however an increased frequency of mutations have been reported at relapse/post-chemotherapy (14-16). Knowledge of Trp53 genetic and functional status in TH-MYCN cell lines is important if they are to be used in preclinical syngeneic neuroblastoma models.
Here we characterised the genetic and functional status of p53 in 6 adherent TH-MYCN transgenic murine cell lines, and demonstrate that 3/6 cell lines have Trp53 mutations and could be used to generate valuable syngeneic models of p53 non-functional relapsed neuroblastoma.
Moreover, we provide evidence of species-dependent selectivity of selected MDM2 inhibitors, which should be considered when selecting murine models for preclinical toxicity testing of MDM2 inhibitors. . NHO2A has been previously described (5) and together with NHO2A mouse tumour DNA were obtained from Michelle Haber (Children's Cancer Institute, Sydney, Australia). All other previously unreported TH-MYCN cell lines were established from the TH-MYCN colony at the Children's Hospital of Philadelphia under an IACUC approved animal protocol. Tumour-bearing mice were euthanized according to humane approved guidelines using isoflurane inhalation followed by cervical dislocation and disinfected with 70% ethanol prior to dissecting the tumour free.
Materials and methods

Cell lines
Tumours were fragmented and filtered through a 40 µm nylon mesh filter into a conical tube, spun-pelleted, and resuspended in sterile Tris Ammonia Chloride buffer, buffered to pH 7.65. 
MDM2 inhibitors, IR, immunoblotting and flow cytometry
MDM2 inhibitors Nutlin-3, MI-63, NDD0005 and RG7388 were obtained, and growth inhibition assays, immunoblotting and flow cytometry performed as previously described (19, 20) . Cells were irradiated using a RS320 irradiator (Gulmay Medical, Surrey, UK). Primary antibodies used were p53 1:1000 (CM5; Leica Microsystems Ltd, UK), MYCN 1:100 (NCMII00; Merck Millipore, Billerica, MA), p21 
Statistical analyses
Two-sided unpaired t-tests were performed using GraphPad Prism v6.0 software with P<0.05 taken as the level of significance.
Results
Trp53 status of TH-MYCN cell lines
All TH-MYCN transgenic cell lines used in the present study were cultured as adherent monolayers ( Figure 1A ). Trp53 Sanger sequencing identified that 3/6 cell lines, NHO2A, To determine whether the mutations present in cell lines were also present in the original tumours or selected for during the establishment of the cell line, tumour DNA was sequenced for Trp53 exons 2-10. Only 1/6 cell lines (NHO2A) had tumour DNA available and was found to be wt ( Figure 1E ).
MYCN and the p53 pathway in TH-MYCN cell lines
Basal expression of MYCN and p53 pathway components, namely p53, MDM2, Figure 4A ).
Species-dependent MDM2 inhibitor selectivity
MDM2 inhibitors are currently under preclinical and clinical evaluation as a novel therapeutic for neuroblastoma. To further evaluate the p53 pathway status of cell lines studied and establish their response to MDM2 inhibitors, sensitivity to Nutlin-3 and additional structurally unrelated MDM2 inhibitors, NDD0005, MI-63 and RG7388 mediated growth inhibition were assessed (Table 2) . Human TP53 wt non-MYCN amplified SHSY5Y and MYCN amplified NGP cells which have previously been shown to be sensitive to the tested MDM2 inhibitors were included as positive controls (19, 20, 22) . The concentrations of Nutlin-3, MI63, NDD0005 and RG7388 which led to 50% growth inhibition (GI50) after 48 hours of treatment are shown in Table 2 . In comparison to TP53 wt human neuroblastoma cells, Trp53 wt control and TH-MYCN murine cell lines were less sensitive to Nutlin-3 mediated growth inhibition as evident by higher GI50 concentrations (1.2-7.4 fold less sensitive; Figure 4C ). Of the tested MDM2 inhibitors, MI-63 and RG7388 were the most potent against the human neuroblastoma cell lines, consistent with our previous studies (19, 22) . The data also revealed that compared with SHSY5Y and NGP cells, Trp53 wt MEF PARP-/-cells were significantly (11.3-15.4 and 11.9-15.0 fold) less sensitive to both MI-63 and RG7388, respectively (Table 2; Figure 4D & E) . Furthermore, the date also show that Trp53 wt TH-MYCN cell lines were significantly (3.5-5.1 fold) less sensitive to MI-63 (Table 2 & Figure 4D ), and even less so (13.6-59.1 fold) to RG7388 (Table 2 & Figure 4E ). This highlights an inverse relationship between potency in TP53 wt human neuroblastoma cells and potency in Trp53 wt murine cells.
Discussion
Cell lines established from primary tumours resected from TH-MYCN mice have been used to develop valuable preclinical immunocompetent, syngeneic models of neuroblastoma More recently, a study of the role of p53 function in neuroblastoma pathogenesis using TH-MYCN murine models observed that loss of p53 function led to reduced survival (29) .
Nutlin-3 is a potent selective inhibitor of the MDM2-p53 interaction (30), previously shown to be highly effective against TP53 wt neuroblastoma cell lines, inducing cell cycle arrest and/or apoptosis, and used to functionally screen large neuroblastoma cell line panels for p53 pathway aberrations (22, 23, 31) . We found that in all cell lines tested, the presence of a mutation was consistent with high basal levels of p53 and aberrant p53 signalling in response to Nutlin-3 and IR, and failure to growth arrest in response to Nutlin-3. Consistent with the mechanism of action of MDM2 inhibitors and existing data from human neuroblastoma cell lines, overall Nutlin-3 was found to induce a cell cycle arrest and/or apoptosis in Trp53 wt control and TH-MYCN murine cell lines (22, 23) . Interestingly in the current study, in response to Nutlin-3 and IR, although there was no induction of p53, an increase in both MDM2 and These observations are consistent with the inter-species selectivity of spiro-oxindole-based MDM2 inhibitors (35) and dihydroisoquinolinone NVP-CGM097 (36) but not pyrazolopyrrolidinone NVP-HDM201 (37, 38) , and should be taken into account when designing studies of MDM2 inhibitors either alone or in combination using either preclinical transgenic or human tumour xenograft models as p53-dependent normal tissue toxicity will not be adequately modelled.
Currently, murine neuroblastoma models include genetically engineered mouse models, syngeneic models, and subcutaneous, orthotopic, pseudometastatic and patient-derived xenografts (3, (39) (40) (41) (42) . All models have associated advantages and disadvantages, and it is likely that the most comprehensive preclinical assessment of efficacy will include a combination of 
